Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
CMPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.27 - $4.08
Previous CloseN/A
Volume16.21M
Average Volume (3M)1.36M
Market Cap
$634.82M
Enterprise Value$268.49M
Total Cash (Recent Filing)$100.95M
Total Debt (Recent Filing)$9.90M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 06, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding171,572,500
10 Day Avg. Volume1,680,559
30 Day Avg. Volume1,364,920
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-731.58
Enterprise Value/Ebitda-4.03
Forecast
1Y Price Target
$12.29Price Target Upside232.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe trial achieved statistical significance in the primary endpoint of overall response rate, showing better results for tovecimig + paclitaxel compared to paclitaxel alone.
Market PositionCompass is well positioned to capitalize on the growing interest in VEGF bispecifics, inclusive of prosecuting a proof-of-concept study for their novel PD-1 x VEGF-A asset CTX-10726.
Product DevelopmentCompass Therapeutics announced positive topline results on the primary efficacy endpoint for COMPANION-002, the company's ongoing Phase 2/3 randomized study of tovecimig in combination with paclitaxel in patients with advanced BTC.
Bears Say
Operational ChallengesManagement acknowledged that the decrease in deaths may benefit from crossover to tovecimig, although only ~50% of patients have crossed over, suggesting that the median OS could be substantially impacted by the 50% that did not cross over.
Valuation ConcernsThe valuation is predicated on a ~3x EV/5-year forward sales estimate, which is a premium to the small cap peer group trading at ~1x.
Compass Therapeutics News
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $1.27 and its highest was $4.08 in the past 12 months.
What is Compass Therapeutics’s market cap?
Compass Therapeutics’s market cap is $634.82M.
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 30 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.124 by -$0.016.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 171,572,500 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.124. Following the earnings report the stock price went up 23.704%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Currently, no hedge funds are holding shares in CMPX
Compass Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.29 (232.16% Upside)
$12.29 (232.16% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 547.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.73%
12-Months-Change
Fundamentals
Return on Equity
-51.84%
Trailing 12-Months
Asset Growth
-25.01%
Trailing 12-Months
Company Description
Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
CMPX Earnings Call
Q2 2025
0:00 / 0:00
CMPX Stock 12 Month Forecast
Average Price Target
$12.29
▲(232.16% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
CytomX Therapeutics
―
Gossamer Bio
―
Bicycle Therapeutics
―
Monopar Therapeutics Inc
―
Ownership Overview
21.95% Insiders
5.44% Mutual Funds
48.34% Other Institutional Investors
19.60% Public Companies and
Individual Investors